HOTH - Hoth adds 39% as mouse model shows proof-of-concept for Alzheimer's candidate

• The nano-cap biopharma Hoth Therapeutics ( NASDAQ: HOTH ) jumped ~39% in the morning hours Tuesday after the company announced proof-of-concept data supporting its Alzheimer’s candidate HT-ALZ based on a mouse model.
• The chronic oral dosing of HT-ALZ over more than five weeks led to significant improvement in behavioral and cognitive function tests in the Alzheimer's mouse model, the company said.
• The study was part of a Sponsored Research Agreement between Hoth ( HOTH ) and Washington University in St. Louis.
• "Chronic dosing had a significant effect on four behavioral deficits that these mice develop due to A? pathology,” noted Dr. John Cirrito an investigator of the study.
• “Such results provide confidence that the investigational treatment is having a meaningful impact in the brain," added Dr. Cirrito who also serves as Associate Professor of Neurology, at the Washington University School of Medicine.
• HT-ALZ is currently undergoing research according to the FDA’s the 505(b)(2) regulatory pathway for the treatment of dementia related to Alzheimer's disease.

For further details see: